Yusuke Tanigawara

37PUBLICATIONS
128CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyCancer geneticsMolecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Dec 19, 2025
IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.

Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe

|Aug 07, 2025
Allelic Imbalance and Chromothripsis Lead to Diversity in Japanese Tumor Genomes With Whole-Genome Duplication.

Keiichi Hatakeyama, Takeshi Nagashima, Sumiko Ohnami

|Jul 12, 2025
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer.

Taichi Miyawaki, Hirotsugu Kenmotsu, Ryo Ko

|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.

Enriqueta Felip, Nasser Altorki, Caicun Zhou

|Oct 11, 2024
Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non-Small Cell Lung Cancer: Old or New Regimen?

Hirotsugu Kenmotsu

Pageof 7

Frequent Collaborators

6 joint publications

Haruyasu Murakami

5 joint publications

Yuichiro Ohe

4 joint publications

Yutaka Fujiwara

4 joint publications

Kazushige Wakuda